Pharmacokinetics of CGP 36 742, an orally active GABAB antagonist, in humans

Journal of Clinical Pharmacology

Volumn 36, Issue 5, 1996, Pages 428-438

  Gleiter, Christoph H ^a   Farger, Gisbert ^b   Möbius, Hans Jörg ^c  

^a UNIVERSITY OF GÖTTINGEN   (Germany)

^b Ciba Holding Deutschland GmbH   (Germany)

^c CIBA GEIGY LTD   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

3 AMINOPROPYLBUTYLPHOSPHINIC ACID; 4 AMINOBUTYRIC ACID B RECEPTOR; 4 AMINOBUTYRIC ACID RECEPTOR BLOCKING AGENT;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DETERMINATION; DRUG HALF LIFE; FATIGUE; FOOD DRUG INTERACTION; GASTROINTESTINAL SYMPTOM; HEADACHE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY CLEARANCE; MALE; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; RANDOMIZED CONTROLLED TRIAL; VERTIGO;

ADMINISTRATION, ORAL; ADULT; AGING; BIOLOGICAL AVAILABILITY; CROSS-OVER STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; GABA ANTAGONISTS; HUMANS; MALE; ORGANOPHOSPHORUS COMPOUNDS; PILOT PROJECTS; RECEPTORS, GABA-B; SEX FACTORS;

EID: 0029972122     PISSN: 00912700     EISSN: None     Source Type: Journal    
DOI: 10.1002/j.1552-4604.1996.tb05030.x     Document Type: Article

References (17)

1. B receptors as targets for drug action. Arzneim-Forsch/Drug Res 1992;42:215-223.
2. Kerr DIB, Ong J, Prager RH, Gynther BD, Curtis DR: Phaclofen, a peripheral and central baclofen antagonist. Brain Res 1987;405: 150-154.
3. B receptors. Eur J Pharmacol 1990;187:27-38.
4. B receptor antagonists: from synthesis to therapeutic applications. Trends Pharmacol Sci 1993;14:391-394.
5. B receptor blockade improves the cognitive performance of mice, rats, and Rhesus monkeys. Pharmacol Commun 1992;2:93-97.
6. B receptor antagonists: potential new anti-absence drugs. J Neural Transm [Gen Sect] 1992;35:179-188.
7. Meinck HM, Tronnier V, Rieke K, Wirtz CR, Flügel D, Schwab S: Intrathecal baclofen treatment for stiff-man syndrome: pump failure may be fatal. Neurology 1994;44:2209-2210
8. B antagonists: potential new drugs. Pharmacol Commun 1992;2:70-74.
9. B antagonist CGP 36 742 by a new GC-MS method. J Biochem Pharmacol (in press).
10. B blocker improves the cognitive performance of mice, rats, and Rhesus monkeys. Behav Neural Biol 1993;60:62-68.
11. B receptor antagonist, facilitates memory in a social recognition test in rats. Behav Brain Res (in press).
12. Udenfriend S, Stein S, Bohlen P, Dairman W, Leimgruber W, Weigele M: Fluorescamine: a reagent for assay of amino acids, peptides, proteins and primary amines in the picomole range. Science 1972;178;871-872.
13. Nutt JG, Woodward WR, Hammerstad JP, Carter JH, Anderson JL: The "on-off" phenomenon in Parkinson's disease: relation to levodopa absorption and transport. N Engl J Med 1984;310:483-488.
14. Ochs GA, Reimann IW: Baclofen Intrathekal. Stuttgart, New York: Thieme, 1995.
15. Davis KL and the Tacrine Collaborative Study Group: A double-blind, placebo-controlled multicenter study of tacrine for Alzheimer's disease. N Engl J Med 1992;327:1253-1259.
16. Brioni JD: Role of GABA during the multiple consolidation of memory. Drug Dev Res 1993;28:3-27.
17. B recptor antagonist CGP 36 742 and the nootropic oxiracetam facilitate the formation of long-term memory. Behav Brain Res (in press).